DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021802/S-024
NDA 021278/S-015

SUPPLEMENT APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Yifeng Jia, Ph.D.
Regional Brand Regulatory Manager
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Jia:

Please refer to your supplemental new drug applications dated and received January 24, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Focalin (dexmethylphenidate hydrochloride) 2.5mg, 5mg, and 10mg Tablets (NDA 021278/S-015) and Focalin XR (dexmethylphenidate hydrochloride) 5mg, 10mg, 15mg, 20mg, 25 mg, 30mg, 35 mg, and 40mg Extended-Release Capsules (NDA 021802/S-024).

Reference is also made to an Agency "Prior Approval" supplement request letter dated January 17, 2012, requesting labeling revisions to add "angioedema" and "anaphylaxis". These adverse events were identified by the Agency in preparation of a Pediatric Advisory Committee held on 1/30-31/2012.

These "Prior Approval" supplemental new drug applications provide for the following changes to product labeling:

1. The addition of a new subsection under **ADVERSE REACTIONS** entitled **Postmarketing Experience**.
2. Revisions to the **CONTRAINDICATIONS-Hypersensitivity to Methylphenidate** section.
3. Revisions to the Medication Guide under **Other serious side effects include**.

Additionally, and as communicated in our January 17, 2012 Agency letter (comment #2), we request the you perform a full review of your post-marketing adverse reaction data and

- "Include only adverse reactions that are clinically significant and plausibly related to treatment with dexmethylphenidate. If any of these adverse reactions are already included in labeling, do not include them in the postmarketing section"

Labeling
As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication

Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Juliette Touré, Regulatory Project Manager, at Juliette.Toure@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
05/02/2012